1 - 25 of
76 for companies in category
Delivery:
Develops Nanobodies, antibody-derived therapeutic proteins that contain the unique structural and functional properties of naturally-occurring heavy-chain antibodies.
The company's nab™ drug delivery technology uses albumin nanoparticles to deliver drugs into tumors.
Access' lead anticancer program is ProLindac™ applies the principals of nanoparticulate prodrugs to enhance the delivery of a platinum drug to tumors.
The company has developed a proprietary formulation technology called HDDS that converts drugs that do not dissolve well in water, or hydrophobic drugs, into microparticles or nanoparticles of the drug embedded in small microspheres, such that the drug can more rapidly dissolve in water.
Manufactures nanoparticulate antibacterial dressings.
Aposense is a clinical stage molecular imaging and drug development company, focused on the introduction of novel agents based on the identification and targeting of cells undergoing apoptosis (programmed cell death).
Develops and manufactures micelle-like nanoparticulate encapsulation technology for applications in food, cosmetics, pharmaceuticals and biotechnology.
Designs, engineers and fabricates coatings, capsules, and "Artificial Cells" from polymers called polypeptides by a method called layer-by-layer self-assembly (LBL).
A biotechnology company engaged in the development and delivery of novel protein and cellular based therapies through design of proprietary Biological Nano Particles.
Avidimer Therapeutics develops and commercializes pharmaceuticals, called avidimers, based on proprietary nanotechnology. Avidimers are "smart drugs" designed to maximize damage to disease targets while minimizing collateral damage to healthy tissue.
Axialys is a science company using nanotechnology based delivery systems to engineer high performance materials for the health and beauty industries.
A specialty pharmaceutical company with a novel drug delivery system. Its proprietary Protein Stabilized Liposomes nanotechnology platform addresses the significant problems associated with delivery of water insoluble drugs.
The company's he Bioral® drug delivery technology encapsulates the selected drug in a nanocrystalline structure termed a "cochleate" cylinder.
Manufactures a nanoparticle-based drug delivery platform.
Develops amphiphilic self-assembling nanocapsules and planar membranes for drug delivery.
The company's Bioral drug delivery technology encapsulates the selected drug in a nanocrystalline structure termed a 'cochleate' cylinder. All of the components of the cochleate cylinder are naturally occurring substances. It is believed that the cochleate cylinder provides an effective delivery mechanism without forming a chemical bond, or otherwise chemically altering, the selected drug.
Develops nanotechnology drug delivery systems based on novel nanomaterials that provide precise control over location and timing of drug delivery.
The company is developing its proprietary calcium phosphate nanotechnology (CAP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems.
A nanotechnology licensing company that provides custom engineered chemical treatments using nano-scale infusion technologies that are configured to the unique requirements of a variety of industrial applications.
Calando combines proprietary technologies in targeted polymeric nanoparticle delivery systems and siRNA design to create effective therapeutics.
Camurus specializes in the development of pharmaceuticals based on advanced and effective innovative nanoscale drug delivery systems that optimize the bioavailability and therapeutic performance of a wide range of difficult substances, including: peptides, proteins, and insoluble small molecules.
Develops nanotechnology-based advanced drug delivery carriers, medical devices and diagnostic particles.
Commercializes a nano and micron sized ceramic spheres technology that provides encapsulation and controlled release of active molecules for a variety of applications including drug delivery, cosmeceuticals and speciality chemicals.
The company develops nanoparticle-based gene therapies for eye disease.
Developed a technology to compact DNA into complexes containing only a single molecule of DNA, resulting in a volume 30-1000 times smaller than other complexes. This simple difference makes Copernicus' "DNA nanoparticles" highly stable and uniquely able to deliver DNA to the nuclei of non-dividing human cells - which includes most cells in the body.
